Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 493-500

  Gelman, Irwin H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cyclin; Metastasis; Microenvironment; Neovascularization; PKA; PKC; Src; SSeCKS AKAP12

Indexed keywords

AKAP12 PROTEIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL AGING; DOWN REGULATION; HUMAN; KIDNEY METASTASIS; LIVER METASTASIS; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

A KINASE ANCHOR PROTEINS; ANIMALS; CELL AGING; CELL CYCLE PROTEINS; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84867979923     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9360-1     Document Type: Article

References (83)

1. Gelman, I. H. (2010). Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes & Cancer, 1(11), 1147-1156.
2. Malbon, C. C. (2007). A-kinase anchoring proteins: trafficking in G-protein-coupled receptors and the proteins that regulate receptor biology. Current Opinion in Drug Discovery & Development, 10(5), 573-579.
3. Lee, H. S.; Han, J.; Bai, H. J.; & Kim, K. W. (2009). Brain angiogenesis in developmental and pathological processes: regulation, molecular and cellular communication at the neurovascular interface. FEBS Journal, 276(17), 4622-4635.
4. Zan, L.; Wu, H.; Jiang, J.; Zhao, S.; Song, Y.; Teng, G.; et al. (2011). Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema. Neurochemistry International, 58(8), 872-879.
5. Gordon, T.; Grove, B.; Loftus, J. C.; O'Toole, T.; McMillan, R.; Lindstrom, J.; et al. (1992). Molecular cloning and prelimnary characteriztion of a novel cytoplasmic antigen recognized by myasthenia gravis sera. Journal of Clinical Investigation, 90, 992-999.
6. Sasaki, H.; Kunimatsu, M.; Funii, Y.; Yamakawa, Y.; Fukai, I.; Kiriyama, M.; et al. (2001). Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis. Surgery Today, 31(11), 1036-1037.
7. Lin, X.; Tombler, E.; Nelson, P. J.; Ross, M.; & Gelman, I. H. (1996). A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. Journal of Biological Chemistry, 271(45), 28430-28438.
8. Chapline, C.; Mousseau, B.; Ramsay, K.; Duddy, S.; Li, Y.; Kiley, S. C.; et al. (1996). Identification of a major protein kinase C-binding protein and substrate in rat embryo fibroblastsdecreased expression in transformed cells. Journal of Biological Chemistry, 271, 6417-6422.
9. Nauert, J.; Klauck, T.; Langeberg, L. K.; & Scott, J. D. (1997). Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffolding protein. Current Biology, 7, 52-62.
10. Burack, W. R.; & Shaw, A. S. (2000). Signal transduction: hanging on a scaffold. Current Opinion in Cell Biology, 12(2), 211-216.
11. Johnson, G. (2002). Signal transductionscaffolding proteinsmore than meets the eye. Science, 295(5558), 1249-1250.
12. Xia, W.; & Gelman, I. H. (2002). Mitogen- and FAK-regulated tyrosine phosphorylation of the SSeCKS scaffolding protein modulates its actin-binding properties. Experimental Cell Research, 277(2), 139-151.
13. Yan, X.; Walkiewicz, M.; Carlson, J.; Leiphon, L.; & Grove, B. (2009). Gravin dynamics regulates the subcellular distribution of PKA. Experimental Cell Research, 315(7), 1247-1259.
14. Gao, S.; Wang, H. Y.; & Malbon, C. C. (2011). AKAP5 and AKAP12 form homo-oligomers. Journal of Molecular Signaling, 6(1), 3.
15. Gao, S.; Wang, H. Y.; & Malbon, C. C. (2011). AKAP12 and AKAP5 form higher-order hetero-oligomers. Journal of Molecular Signaling, 6(1), 8.
16. Guo, L. W.; Gao, L.; Rothschild, J.; Su, B.; & Gelman, I. H. (2011). Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12. Journal of Biological Chemistry, 286(44), 38356-38366.
17. Lin, X.; Nelson, P.; & Gelman, I. H. (2000). Regulation of G-> S progression by the SSeCKS tumor suppressor: control of cyclin D expression and cellular compartmentalization. Molecular and Cellular Biology, 20(19), 7259-7272.
18. Akakura, S.; Huang, C.; Nelson, P. J.; Foster, B.; & Gelman, I. H. (2008). Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Research, 68(13), 5096-5103.
19. Kwon, H. B.; Choi, Y. K.; Lim, J. J.; Kwon, S. H.; Her, S.; Kim, H. J.; et al. (2011). AKAP12 regulates vascular integrity in zebrafish. Experimental & Molecular Medicine, 44(3), 225-235.
20. Gelman, I. H. (2002). The role of the SSeCKS/Gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Frontiers in Bioscience, 7, d1782-d1797.
21. Lin, X.; & Gelman, I. H. (1997). Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Research, 57, 2304-2312.
22. Akakura, S.; Nochajski, P.; Gao, L.; Sotomayor, P.; Matsui, S.; & Gelman, I. H. (2010). Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle, 9(23), 4656-4665.
23. Weinberg, R. A. (1995). The molecular basis of oncogenes and tumor suppressor genes. Annals of the New York Academy of Science, 758, 331-338.
24. Xia, W.; Unger, P.; Miller, L.; Nelson, J.; & Gelman, I. H. (2001). The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Research, 61(14), 5644-5651.
25. Lapointe, J.; Li, C.; Giacomini, C. P.; Salari, K.; Huang, S.; Wang, P.; et al. (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Research, 67(18), 8504-8510.
26. Streb, J. W.; Kitchen, C. M.; Gelman, I. H.; & Miano, J. M. (2004). Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. Journal of Biological Chemistry, 279(53), 56014-56023.
27. Bu, Y.; & Gelman, I. H. (2007). v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. Journal of Biological Chemistry, 282(37), 26725-26739.
28. Bu, Y.; Gao, L.; & Gelman, I. H. (2010). Role for transcription factor TFII-I in the suppression Of SSeCKS/Gravin/Akap12 transcription by Src. International Journal of Cancer, 128(8), 1836-1842.
29. Choi, M. C.; Jong, H. S.; Kim, T. Y.; Song, S. H.; Lee, D. S.; Lee, J. W.; et al. (2004). AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene, 23(42), 7095-7103.
30. Jo, U.; Whang, Y. M.; Kim, H. K.; & Kim, Y. H. (2009). AKAP12alpha is associated with promoter methylation in lung cancer. Cancer Research and Treatment, 38(3), 144-151.
31. Tessema, M.; Willink, R.; Do, K.; Yu, Y. Y.; Yu, W.; Machida, E. O.; et al. (2008). Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Research, 68(6), 1707-1714.
32. Bonazzi, V. F.; Irwin, D.; & Hayward, N. K. (2009). Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes, Chromosomes & Cancer, 48(1), 10-21.
33. Mori, Y.; Cai, K.; Cheng, Y.; Wang, S.; Paun, B.; Hamilton, J. P.; et al. (2006). A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology, 131(3), 797-808.
34. Liu, W.; Guan, M.; Su, B.; Ye, C.; Li, J.; Zhang, X.; et al. (2010). Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with dukes' stage. Cancer Biology & Therapy, 9(11), 862-871.
35. Liu, W.; Gong, J.; Hu, J.; Hu, T.; Sun, Y.; Du, J.; et al. (2011). Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score. Urology, 77(4), 1006e1-1006e7.
36. Wu, W.; Zhang, J.; Yang, H.; Shao, Y.; & Yu, B. (2010). Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis. Clinical and Experimental Dermatology, 36(4), 381-385.
37. Mardin, W.; Petrov, K.; Enns, A.; Senninger, N.; Haier, J.; & Mees, S. (2010). SERPINB5 and AKAP12expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma. BMC Cancer, 10(1), 549.
38. Heller, G.; Schmidt, W. M.; Ziegler, B.; Holzer, S.; Mullauer, L.; Bilban, M.; et al. (2008). Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Research, 68(1), 44-54.
39. Wang, J.; Qin, R.; Ma, Y.; Wu, H.; Peters, H.; Tyska, M.; et al. (2009). Differential gene expression in normal esophagus and Barrett's esophagus. Journal of Gastroenterology, 44(9), 897-911.
40. Jin, Z.; Cheng, Y.; Gu, W.; Zheng, Y.; Sato, F.; Mori, Y.; et al. (2009). A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Research, 69(10), 4112-4115.
41. Jin, Z.; Hamilton, J. P.; Yang, J.; Mori, Y.; Olaru, A.; Sato, F.; et al. (2008). Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiology, Biomarkers & Prevention, 17(1), 111-117.
42. Cai, Q.; Wen, W.; Qu, S.; Li, G.; Egan, K. M.; Chen, K.; et al. (2011). Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European ancestry. Cancer Research, 71(4), 1344-1355.
43. He, M. L.; Chen, Y.; Chen, Q.; He, Y.; Zhao, J.; Wang, J.; et al. (2011). Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study. American Journal of Cancer Research, 1(4), 562-573.
44. Hayashi, M.; Nomoto, S.; Kanda, M.; Okamura, Y.; Nishikawa, Y.; Yamada, S.; et al. (2012). Identification of the a kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. Journal of Surgical Oncology, 105(4), 381-386.
45. Kim, D. H.; Lee, S. T.; Won, H. H.; Kim, S.; Kim, M. J.; Kim, H. J.; et al. (2011). A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood, 117(25), 6906-6911.
46. Daoud, S. S.; Munson, P. J.; Reinhold, W.; Young, L.; Prabhu, V. V.; Yu, Q.; et al. (2003). Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Research, 63(11), 2782-2793.
47. Zhang, X.; Ma, L.; Enkemann, S. A.; & Pledger, W. J. (2003). Role of Gadd45alpha in the density-dependent G1 arrest induced by p27(Kip1). Oncogene, 22(27), 4166-4174.
48. Yoo, J. Y.; Huso, D. L.; Nathans, D.; & Desiderio, S. (2002). Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell, 108(3), 331-344.
49. Chen, J.; Maltby, K. M.; & Miano, J. M. (2001). A novel retinoid-response gene set in vascular smooth muscle cells. Biochemistry and Biophysics Research Communications, 281(2), 475-482.
50. Streb, J. W.; Long, X.; Lee, T. H.; Sun, Q.; Kitchen, C. M.; Georger, M. A.; et al. (2011). Retinoid-induced expression and activity of an immediate early tumor suppressor gene in vascular smooth muscle cells. PLoS One, 6(4), e18538.
51. Palmer, H. G.; Sanchez-Carbayo, M.; Ordonez-Moran, P.; Larriba, M. J.; Cordon-Cardo, C.; & Munoz, A. (2003). Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Research, 63(22), 7799-7806.
52. Kovalenko, P. L.; Zhang, Z.; Cui, M.; Clinton, S. K.; & Fleet, J. C. (2010). 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics, 11, 26.
53. Ali, N. A.; McKay, M. J.; & Molloy, M. P. (2010). Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Molecular BioSystems, 6(11), 2332-2338.
54. 0 phase and serum response. Molecular and Cellular Biochemistry, 175, 233-241.
55. Nelson, P. S.; Clegg, N.; Arnold, H.; Ferguson, C.; Bonham, M.; White, J.; et al. (2002). The program of androgen-responsive genes in neoplastic prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11890-11895.
56. Shao, C.; Wang, Y.; Yue, H. H.; Zhang, Y. T.; Shi, C. H.; Liu, F.; et al. (2007). Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. Journal of Andrology, 28(6), 804-812.
57. Nickols, N. G.; & Dervan, P. B. (2007). Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proceedings of the National Academy of Sciences of the United States of America, 104(25), 10418-10423.
58. Singh, A. P.; Bafna, S.; Chaudhary, K.; Venkatraman, G.; Smith, L.; Eudy, J. D.; et al. (2008). Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Letters, 259(1), 28-38.
59. Cohen, S. B.; Waha, A.; Gelman, I. H.; & Vogt, P. K. (2001). Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10 T1/2 murine fibroblasts. Oncogene, 20(2), 141-146.
60. Gelman, I. H.; & Gao, L. (2006). The SSeCKS/Gravin/AKAP12 Metastasis Suppressor Inhibits Podosome Formation Via RhoA- and Cdc42-Dependent Pathways. Molecular Cancer Research, 4(3), 151-158.
61. Nelson, P. J.; Moissoglu, K.; Vargas, J. J.; Klotman, P. E.; & Gelman, I. H. (1999). Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. Journal of Cell Science, 112(3), 361-370.
62. Lee, S. W.; Jung, K. H.; Jeong, C. H.; Seo, J. H.; Yoon, D. K.; Suh, J. K.; et al. (2011). Inhibition of endothelial cell migration through the downregulation of MMP-9 by A-kinase anchoring protein 12. Molecular Medicine Report, 4(1), 145-149.
63. Su, B.; Bu, Y.; Engelberg, D.; & Gelman, I. H. (2010). SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a PKC-RAF/MEK/ERK pathway. Journal of Biological Chemistry, 285(7), 4578-4586.
64. B Su, L Gao, F Meng, L-W Guo, J Rothschild & IH Gelman (in press). Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12, Oncogene.
65. Lee, H.; Volonte, D.; Galbiati, F.; Iyengar, P.; Lublin, D. M.; Bregman, D. B.; et al. (2000). Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Molecular Endocrinology, 14(11), 1750-1775.
66. Rinker-Schaeffer, C. W.; O'Keefe, J. P.; Welch, D. R.; & Theodorescu, D. (2006). Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clinical Cancer Research, 12(13), 3882-3889.
67. Su, B.; Zheng, Q.; Vaughan, M. M.; Bu, Y.; & Gelman, I. H. (2006). SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with VEGF inhibition. Cancer Research, 66(11), 5599-5607.
68. Eliceiri, B. P.; Paul, R.; Schwartzberg, P. L.; Hood, J. D.; Leng, J.; & Cheresh, D. A. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Molecular Cell, 4(6), 915-924.
69. Eliceiri, B. P.; Puente, X. S.; Hood, J. D.; Stupack, D. G.; Schlaepfer, D. D.; Huang, X. Z. Z.; et al. (2002). Src-mediated coupling of focal adhesion kinase to integrin alpha v beta 5 in vascular endothelial growth factor signaling. The Journal of Cell Biology, 157(1), 149-159.
70. Weis, S.; Cui, J.; Barnes, L.; & Cheresh, D. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology, 167(2), 223-229.
71. Lee, S. W.; Kim, W. J.; Choi, Y. K.; Song, H. S.; Son, M. J.; Gelman, I. H.; et al. (2003). SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nature Medicine, 9(7), 900-906.
72. Adluri, R. S.; Thirunavukkarasu, M.; Zhan, L.; Akita, Y.; Samuel, S. M.; Otani, H.; et al. (2011). Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. Journal of Molecular and Cellular Cardiology, 50(1), 239-247.
73. Choi, Y. K.; Kim, J. H.; Kim, W. J.; Lee, H. Y.; Park, J. A.; Lee, S. W.; et al. (2007). AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. Journal of Neuroscience, 27(16), 4472-4481.
74. Choi, Y. K.; & Kim, K. W. (2008). AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. FEBS Journal, 275(9), 2338-2353.
75. Steagall, R. J.; Hua, F.; Thirunazukarasu, M.; Zhan, L.; Li, C.; Maulik, N.; et al. (2010). HspA12B promotes angiogenesis through suppressing AKAP12 and up-regulating VEGF pathway. Angiogenesis, 118, S449.
76. Liu, W.; Guan, M.; Hu, T.; Gu, X.; & Lu, Y. (2011). Re-expression of AKAP12 inhibits progression and metastasis potential of colorectal carcinoma in vivo and in vitro. PLoS One, 6(8), e24015.
77. Akakura, S.; Bouchard, R.; Bshara, W.; Morrison, C.; & Gelman, I. H. (2010). Carcinogen-induced squamous papillomas and oncogenic progression in the absence of the SSeCKS/AKAP12 metastasis suppressor correlates with FAK upregulation. International Journal of Cancer, 129(8), 2025-2031.
78. Ohtani, N.; Mann, D. J.; & Hara, E. (2009). Cellular senescence: its role in tumor suppression and aging. Cancer Science, 100(5), 792-797.
79. McLean, G. W.; Brown, K.; Arbuckle, M. I.; Wyke, A. W.; Pikkarainen, T.; Ruoslahti, E.; et al. (2001). Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis. Cancer Research, 61(23), 8385-8389.
80. Akakura, S.; Su, B.; Nochajski, P.; Foster, B.; Huang, C.; Nelson, P. J.; et al. (2009). SSeCKS/Gravin/AKAP12 suppresses metastasis through tumor- and microenvironment-specific pathways. Clinical & Experimental Metastasis, 26(7), 864(A49).
81. Daigeler, A.; Klein-Hitpass, L.; Chromik, M. A.; Muller, O.; Hauser, J.; Homann, H. H.; et al. (2008). Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer, 8, 313.
82. Harlin, H.; Meng, Y.; Peterson, A. C.; Zha, Y.; Tretiakova, M.; Slingluff, C.; et al. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Research, 69(7), 3077-3085.
83. Radvanyi, L.; Singh-Sandhu, D.; Gallichan, S.; Lovitt, C.; Pedyczak, A.; Mallo, G.; et al. (2005). The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 102(31), 11005-11010.